Deep neuromascular blockage

PreclinicalSmall molecule

Deep neuromascular blockage is one of 5 small molecule programs targeting Neuromuscular Blockade. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Neuromuscular BlockadeNot yet recruiting

Neuromuscular BlockadePreclinical

Not yet recruiting

Competition

Competitive Landscape

7 competitors in Neuromuscular Blockade

#DrugCompanyPhaseTrials

Arduan

OOrganon and Co

Approved

2 2

HRS-9190

JJiangsu HengRui Medicine Co., Ltd.

Phase 3

1 3

Conventional Dose CRRT

SSeoul National University Hospital

Preclinical

1 4

Deep neuromascular blockage

UUniversity Hospital of Patras

Preclinical

1 5

Profound Neuromuscular Blockade

SSheba Medical Center

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Neuromuscular Blockade1 trial

Deep Versus Moderate Neuromuscular Blockade in Bariatric Surgery

Not yet recruiting·UUniversity Hospital of Patras·N/A·NCT06553066·50 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Deep neuromascular blockage. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Deep neuromascular blockage compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Deep neuromascular blockage. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — University Hospital of Patras company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: UUniversity Hospital of Patras

Deep neuromascular blockage

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Neuromuscular Blockade1 trial

References

Drug Info

Quick Facts

Related News